-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
More than 70% of breast cancer patients are positive for hormones, characterized by estrogen-positive (ER-plus), progesterone-positive (PgR-plus), or both.
ER-positive has important prognosmical value and is the main predictive indicator of endocrine therapy (ET) sensitivity.
, however, up to 50% of patients with ER-plus breast cancer do not respond to ET treatment.
, the search for more accurate predictive biomarkers is imminent.
previous studies have shown that transcription of PgR is directly regulated by estrogen.
, PgR levels rise only when ER functions properly and estrogen is present.
these limitations also led to inconsistent results in clinical studies that assessed the value of PgR in predicting ET effects.
clearly, there is a need for better ways to determine the level and functional status of tumor ER and PgR in order to better identify the patients most likely to benefit from ET treatment.
hypothesization that short-lived esodiol therapy would only raise PgR levels in tumors with functional ER.
respondents and non-respondents in this prospective Phase 2 single-center one-arm trial (NCT02455453), the researchers reported a correlation between the patient's response to ET the day before and after estradiol treatment and the intake of progesterone-like (21- .18F) fluorofuran dethylaminate, FFNP).
Overall survival results In 43 post-menoanthorum women with ER-plus breast cancer, the researchers found that only 28 subjects (respondents) who had a clinical benefit from ET had an increased intake of tumor FFNP, while 15 patients who did not have a clinical benefit (no respondents) had an increase in FFNP intake, indicating 100 percent sensitivity and specificity of the change.
further studies have shown that subjects who responded survived significantly longer.
, the results show that changes in tumor FFNP intake after esodiol therapy can highly predict the response of women with ER-plus breast cancer to ET treatment.
